Atlantic Research Group To Sponsor ALS Drug Development Summit May 16-18 in Boston

Atlantic Research Group To Sponsor ALS Drug Development Summit May 16-18 in Boston

Atlantic Research Group (ARG) will be acting as a sponsor for the 2nd annual ALS Drug Development Summit in Boston May 16-18. The event will feature over 35 expert ALS speakers across three jam-packed conference days, spanning all stages of the drug development pipeline.

With exciting regulatory firsts, booming pharma investment, and new biotechs entering the field, the ALS drug development landscape is gaining momentum and positivity. However, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population. The ALS Drug Development Summit is the only industry-focused conference dedicated to overcoming preclinical clinical challenges currently facing ALS pipelines.

ARG, a proud event partner of the ALS Drug Development Summit, is firmly committed to the neurodegenerative diseases community. Neurological diseases such as ALS/MND are very challenging for patients in clinical trials. As a result, it is imperative that CRO study teams have experience in and understanding of neurology studies in order to foster patient centricity.

All of the stakeholders must be taken into account in order to create a stable project environment. Trusted by chief investigators at leading sites, ARG’s knowledge and understanding of the US and European regulatory environment and processes means that the trials we manage are largely free from the impediments and duplication of efforts that can be associated with multi-site projects.

Our repeated success over time in neurodegenerative studies is rooted in our long-term commitment to knowledge, relationships, patients, and treatments. Ignazio Di Giovanna, PhD, VP, Scientific Affairs, Neurology will be attending the Summit. To arrange a discussion, please contact Ignazio at [email protected]